The combination of PD-L1 inhibitors like atezolizumab and durvalumab with chemotherapy has enhanced the OS of SCLC patients by 2–3 months since they were approved as first-line treatments for SCLC by the Food and Drug Administration (FDA) (12, 13). The gene discussed is CD274; the disease is small cell lung carcinoma.